B. Laffranchi

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom et al. · Journal of Clinical Oncology · 2009 · 105 citations

Medicine, Oncology, Pharmacology +15

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal et al. · Clinical Cancer Research · 2009 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors

Christophe Massard, Jean‐Charles Soria, Alan Anthoney et al. · Cell Cycle · 2011 · 54 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Ronald Paquette, Neil P. Shah, Charles L. Sawyers et al. · Blood · 2007 · 53 citations

Medicine, Hematology, Oncology +9

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Jörge E. Cortes, Hervé Dombret, Philippe Schafhausen et al. · Blood · 2009 · 44 citations

Medicine, Oncology, Pharmacology +15